» Articles » PMID: 34339764

Prevention of NAFLD-associated HCC: Role of Lifestyle and Chemoprevention

Overview
Journal J Hepatol
Publisher Elsevier
Specialty Gastroenterology
Date 2021 Aug 2
PMID 34339764
Citations 51
Authors
Affiliations
Soon will be listed here.
Abstract

In many countries worldwide, the burden of hepatocellular carcinoma (HCC) associated with non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is increasing. Preventive strategies are needed to counteract this trend. In this review, we provide an overview of the evidence on preventive strategies in NAFLD-associated HCC. We consider the impact of lifestyle factors such as weight loss, physical activity, smoking, dietary patterns and food items, including coffee and alcohol, on both HCC and NAFLD/NASH. Furthermore, evidence on chemopreventive treatments, including aspirin, antidiabetic treatments and statins is summarised. The role of adjuvant therapies for tertiary prevention of HCC is briefly reviewed.

Citing Articles

Statins decrease the risk of hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: A systematic review and meta-analysis.

Tarar Z, Farooq U, Inayat F, Basida S, Ibrahim F, Gandhi M World J Exp Med. 2024; 14(4):98543.

PMID: 39713070 PMC: 11551700. DOI: 10.5493/wjem.v14.i4.98543.


Dronedarone hydrochloride inhibits gastric cancer proliferation in vitro and in vivo by targeting SRC.

Lu X, Zhang W, Yang X, Yan X, Hussain Z, Wu Q Transl Oncol. 2024; 50:102136.

PMID: 39369581 PMC: 11491965. DOI: 10.1016/j.tranon.2024.102136.


Metabolic dysfunction-associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study.

Park Y, Jung J, Han S, Kim G Aliment Pharmacol Ther. 2024; 60(11-12):1599-1608.

PMID: 39304991 PMC: 11599781. DOI: 10.1111/apt.18286.


Health condition and socioeconomic status mediate the causal effect of reproductive traits on nonalcoholic fatty liver disease: evidence from Mendelian randomization study.

Wang Q, Wang L, Hao R, Zhang L, Wang W, Xia L Front Endocrinol (Lausanne). 2024; 15:1419964.

PMID: 39280015 PMC: 11393784. DOI: 10.3389/fendo.2024.1419964.


Self-management in patients with metabolic dysfunction-associated steatotic liver disease: influencing factors and impact on readmission.

Lin X, Bao S, Yu Y, Huang H, Shu M J Health Popul Nutr. 2024; 43(1):134.

PMID: 39217400 PMC: 11366125. DOI: 10.1186/s41043-024-00618-z.